2025卵巢癌治疗现状与前沿洞察（英）_13页_1mb

KOL Insights: Ovarian Cancer Treatment and Management

Core Content Overview

This document provides insights from a gynecological oncologist specializing in ovarian cancer treatment in the US Northeast. The information covers treatment approaches, patient management, quality of life considerations, and the current and future landscape of therapies for different stages and subtypes of ovarian cancer.

Main Points and Key Information

1. Early-Stage Disease Treatment

• Surgery: Typically performed as a staging procedure. Laparoscopic surgery is common, with recovery usually within 4–6 weeks.
• Adjuvant Chemotherapy: For stages III and IV, patients receive 6 cycles of carboplatin and paclitaxel (Taxol), often combined with bevacizumab (Avastin) maintenance therapy.
• Maintenance Therapy: PARP inhibitors like olaparib (Lynparza) are used for patients with BRCA mutations or HRD-deficient tumors.
• Quality of Life: Generally good, with most patients experiencing reasonable performance status during chemotherapy. They may have one week of discomfort every three cycles, but overall, they are able to maintain a good quality of life.
• Recurrence Rates:
  • Stage I: 5–10% recurrence.
  • Stage II: ~15% recurrence.
• Local vs. Distant Progression: Most early-stage patients develop distant metastatic disease rather than local recurrence.

2. Advanced-Stage Disease Management

• Surgical Eligibility: ~90% of patients are fit for surgery. Of these, ~45% undergo surgery upfront, followed by chemotherapy, while the remaining 55% receive neoadjuvant chemotherapy first.
• Recurrence Rates:
  • Stage III: ~80% recurrence.
  • Stage IV: ~90% recurrence.
• Platinum Resistance: All patients with advanced disease eventually become platinum-resistant. ~5% are initially platinum-refractory.
• Quality of Life: Poorer compared to early-stage patients, due to both cancer-related symptoms and chemotherapy side effects. Most patients experience significant fatigue, neuropathy, and other adverse effects.

3. Treatment of Recurrent Disease

• Platinum-Sensitive Recurrence: Treated with platinum-based doublets, often carboplatin and doxorubicin (Doxil), with maintenance therapy options like Avastin.
• Platinum-Resistant Recurrence:
  • Patients with high FRα expression may receive mirvetuximab (Elahere), which has shown the best response rates (~44–45%).
  • If not eligible for mirvetuximab, treatment options include carboplatin and gemcitabine or single-agent therapies like topotecan or pemetrexed (Alimta), with response rates around 10–15%.

4. Use of Avastin (Bevacizumab)

• First-Line Use: ~35–40% of patients receive Avastin in combination with chemotherapy.
• Biosimilar Use: Most patients in the hospital receive the biosimilar version unless they have an adverse reaction.
• Eligibility Considerations: Patients with recent clotting events, uncontrolled hypertension, or being very old and frail may not be eligible.

5. PARP Inhibitors

• First-Line Maintenance: Olaparib is the most commonly used PARP inhibitor, with rucaparib and niraparib also available but less commonly used.
• Efficacy: PARP inhibitors are effective in patients with BRCA mutations or HRD-deficient tumors, but not in those with BRCA wild-type or HRD-proficient tumors.
• Zejula (niraparib): May be used in patients who are not eligible for olaparib but want PARP inhibitor therapy, particularly for those with platinum-sensitive disease.

6. Pipeline Therapies

• PD-1 Inhibitors: Preliminary data suggest PFS benefits but no OS improvement. Due to low PD-L1 expression (~10–15%) in ovarian cancer, approval is unlikely.
• Stenoparib: Shows efficacy rates over 30%. If data are sustained, it may be approved and could help in decision-making among PARP inhibitors.
• Relacorilant (ROSELLA Trial): Demonstrates PFS and OS benefits over nab-paclitaxel alone. Preliminary data suggest it is likely to move forward.

Summary of Key Treatment Approaches

Unmet Needs and Future Directions

• Platinum-Resistant Setting: There is a need for drugs with longer response duration and higher response rates.
• Specific Histologies:
  • Low-grade serous
  • Clear cell
  • Mucinous tumors
  • These are less responsive to standard treatments and require more tailored approaches.
• Targeted Therapies: Molecular profiling (e.g., FRα, BRCA, HRD) is critical for guiding treatment.
• Clinical Trials: There is a focus on developing better therapies for both platinum-resistant and primary advanced-stage disease.

Conclusion

The current treatment landscape for ovarian cancer is evolving, with a strong emphasis on personalized and molecularly guided therapies. While existing options like PARP inhibitors and Avastin have improved outcomes, there remains a significant unmet need, especially in platinum-resistant and specific histology subtypes. Pipeline therapies, including PD-1 inhibitors and stenoparib, are under evaluation, with some showing promise in specific patient populations. The future of ovarian cancer treatment will likely depend on further clinical data and the development of more targeted and effective therapies.